Mechanism of Action

Potentiates HGF/c-Met signaling to promote synaptogenesis, neuronal spine formation, and new synaptic connections. Oral bioavailability. Crosses blood-brain barrier.

Clinical Use

No approved use. ZERO human clinical trials. Not recommended for clinical use given cancer pathway concern and abandoned development.

Contraindications

CRITICAL: Active cancer or cancer history — HGF/c-Met pathway is directly involved in tumor progression and metastasis.

Evidence Summary

ZERO human clinical trials. Preclinical cognitive effects in impaired animals only. Abandoned by developers. ADDF: no human research data.

Key Studies
  • 1.McCoy AT et al., ACS Chem Neurosci 2013 — bound HGF with high affinity, increased hippocampal neuronal spinogenesis. No effect in rats with normal cognition. Preclinical
Evidence Gaps

ZERO human clinical trials. ZERO human safety data. Abandoned by original developers. Alzheimer's Drug Discovery Foundation: no human research data.

Emerging Research

No active development. Not recommended for clinical use.

iRemedy Sourcing Status
RESEARCH / INVESTIGATIONAL
Research use only — not suitable for compounding given safety profile

iRemedy is a 50-state licensed, NABP-accredited wholesale distributor. Peptides supplied with full CoA, DSCSA serialization, and UPS Healthcare cold chain logistics. Wholesale to licensed healthcare facilities and compounding pharmacies only.

← Back to Peptide Library ← Previous: CJC-1295 Next: DSIP →
Request Peptide Catalog →